HCW Biologics Inc. (HCWB)

HCW Biologics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	2.57	2.84	6.72	-	4.1
Revenue Growth (YoY)	-9.68%	-57.73%	-	-	-
Cost of Revenue	1.61	7.53	4.14	-	-
Gross Profit	0.96	-4.69	2.59	-	4.1
Selling, General & Admin	22.75	13.44	8.41	5.3	2.75
Research & Development	6.39	7.59	9.25	8.07	7.17
Operating Expenses	30.44	21.03	17.67	13.37	9.92
Operating Income	-29.48	-25.72	-15.08	-13.37	-5.82
Interest Expense	-0.63	-0.28	-0.13	-	-
Interest & Investment Income	-	-	-	-	0.02
Other Non Operating Income (Expenses)	0.09	0.74	0.49	-0.06	-
EBT Excluding Unusual Items	-30.02	-25.26	-14.71	-13.43	-5.8
Gain (Loss) on Sale of Investments	-	0.26	-0.19	-	-
Other Unusual Items	-	-	-	0.57	-
Pretax Income	-30.02	-24.99	-14.9	-12.86	-5.8
Net Income	-30.02	-24.99	-14.9	-12.86	-5.8
Preferred Dividends & Other Adjustments	-	-	-	-	1.27
Net Income to Common	-30.02	-24.99	-14.9	-12.86	-7.07
Shares Outstanding (Basic)	39	36	36	19	5
Shares Outstanding (Diluted)	39	36	36	19	5
Shares Change (YoY)	7.97%	0.30%	90.84%	296.07%	10.56%
EPS (Basic)	-0.77	-0.70	-0.42	-0.69	-1.49
EPS (Diluted)	-0.77	-0.70	-0.42	-0.69	-1.49
Free Cash Flow	-14.49	-28.72	-20.66	-11.02	-10.62
Free Cash Flow Per Share	-0.37	-0.80	-0.58	-0.59	-2.24
Gross Margin	37.38%	-165.02%	38.48%	-	100.00%
Operating Margin	-1148.50%	-904.96%	-224.32%	-	-142.07%
Profit Margin	-1169.70%	-879.52%	-221.67%	-	-172.54%
Free Cash Flow Margin	-564.48%	-1010.51%	-307.36%	-	-258.99%
EBITDA	-28.3	-24.91	-14.49	-12.82	-5.25
EBITDA Margin	-	-	-215.55%	-	-128.10%
D&A For EBITDA	1.18	0.81	0.59	0.54	0.57
EBIT	-29.48	-25.72	-15.08	-13.37	-5.82
EBIT Margin	-	-	-224.32%	-	-142.07%
Revenue as Reported	-	-	-	-	4.1

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q